

## Special Issue

# Feature Papers in Section “Cancer Informatics and Big Data”

### Message from the Guest Editor

In the last decade, cancer informatics and big data analytics methods have become a key component in cancer research, as well as in the diagnosis and treatment of cancer. Artificial intelligence-based methods, and other methods utilizing large datasets, are still rapidly developing. In the “Cancer Informatics and Big Data” section of *Cancers*, we have been focusing on publishing research related to novel tools and methods to facilitate research, as well as understanding how to optimally use and exploit large databases and other resources for developing novel cancer therapies and improving cancer care. The goal of this Special Issue of *Cancers*, entitled “Feature Papers in Section “Cancer Informatics and Big Data””, is to share the latest innovations in this field to help facilitate the dissemination of knowledge. We invite and encourage the submission of original research papers, as well as review articles, related to the most important challenges and opportunities in this area.

---

### Guest Editor

Dr. Jason Roszik

Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

---

### Deadline for manuscript submissions

30 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/223504](https://mdpi.com/si/223504)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)